Valuation vs Trend
Strong uptrend on both timeframes, but the multiple is rich. Further upside increasingly depends on earnings delivery rather than re-rating.
←Back to list
JSE ticker · APN
Aspen Pharmacare Hldgs Ltd (APN) Share Price & Latest SENS Announcements
Aspen Pharmacare Holdings Limited
Healthcare · Drug Manufacturers - Specialty & Generic
Track Aspen Pharmacare Holdings Limited (APN) share price moves, recent SENS announcements, company profile details, and Healthcare sector, drug manufacturers - specialty & generic, all in one place.
R 154,44
▲ +9,44 / +6.51%
CLOSE · 03 Sept
MOMENTUM · STRONG
Latest SENS Announcements — Aspen Pharmacare Hldgs Ltd (APN)
10 most recent- 02 Sep Results
ASPEN PHARMACARE HOLDINGS LIMITED - Reviewed Condensed Group Financial Results for the year ended 30 June 2026 and Cash Dividend Declaration
Aspen confirms August guidance with NHEPS 801.5 cents, raises dividend 10%, and guides FY2027 EBITDA to at least R9bn — a fresh…
BULLISH +35 - 02 Sep Share Repurchase
ASPEN PHARMACARE HOLDINGS LIMITED - General repurchase of ordinary shares
Aspen repurchased 13.3m shares (~3% of capital) at R148.17 average, R1.975bn total — an execution notice for an already-disclosed programme.
NEUTRAL 0 - 21 Aug Trading Statement
ASPEN PHARMACARE HOLDINGS LIMITED - Business update and trading statement for the year ended 30 June 2026
Strong operational delivery against a -9.2% sell-off is a genuine positive surprise, not confirmation.
BULLISH +35 - 03 Aug Results
ASPEN PHARMACARE HOLDINGS LIMITED - Notice regarding the Release of Aspens Financial Results for the year ending 30 June 2026, and Results Presentation
Aspen schedules FY2026 results for 2 September 2026 — no financial figures in this notice, just a date-setter.
NEUTRAL 0 - 20 Jul Operational Update
ASPEN PHARMACARE HOLDINGS LIMITED - Health Canada approves Aspen-Semaglutide
Health Canada clears Aspen-Semaglutide for adult T2D — a real de-risking step, with launch still gated on DRL supply.
NEUTRAL +15 - 09 Jul Board/Governance
ASPEN PHARMACARE HOLDINGS LIMITED - Proposed Succession and Board Composition Update
Aspen pre-announces orderly Chair succession: Dlamini out at December 2026 AGM, Kruger named as successor. Governance-only filing, no economic signal.
NEUTRAL 0 - 02 Jul Shareholder Notice
ASPEN PHARMACARE HOLDINGS LIMITED - Notification in terms of Section 122 (3)(b) of the Companies Act and Section 6.54 of the JSE Listings Requirements
PIC crosses into 20.098% of Aspen — a required regulatory filing with no new economic information.
NEUTRAL 0 - 25 Jun Director Dealings
ASPEN PHARMACARE HOLDINGS LIMITED - Dealing in Securities by a Prescribed Officer
Prescribed officer received 44,030 shares worth R6.19m via accelerated vesting of deferred bonus awards — an off-market scheme delivery, not a market trade.
NEUTRAL 0 - 22 Jun Board/Committee Change
ASPEN PHARMACARE HOLDINGS LIMITED - Change in Chairmanship of the Audit and Risk Committee
Aspen announces a chair rotation at its Audit and Risk Committee — pure governance housekeeping with no financial or operational substance disclosed.
NEUTRAL 0 - 29 May Disposal
ASPEN PHARMACARE HOLDINGS LIMITED - Completion of the divestment of Aspen APAC
Aspen completed its APAC divestment, securing an above-estimate R27 billion to reduce debt and fund buybacks.
BULLISH +35
Valuation
Expensive
Growth
Improving
Momentum
Bullish
Volume
Normal
SENS Signal
Positive
Price · Close
- Trend
- Up · above 50 & 200
- Momentum
- Strong
- RSI 14
- 55
- 30D Vol
- 38.6%
52W Range
R 91
R 161
Current: R 154(91% through range)
What Changed
Delta view Today
+6.51%
5 days
-3.79%
30 days
+3.24%
90 days
+10.88%
Year-to-date
+32.24%
vs 50-day MA
+2.79%
vs 200-day MA
+18.18%
Latest SENS 1d ago: "ASPEN PHARMACARE HOLDINGS LIMITED - Reviewed Condensed Group Financial Results for the year ended 30 June 2026 and Cash Dividend Declaration" — reading positive.
Market
Market Cap
R 68.6B
52W High
160.93
52W Low
90.70
52W Pos.
91%
Avg Vol 30D
1.5M
Valuation
P/E (TTM)
25.9×
Fwd EPS
—
Fwd P/E
—
Div Yield
1.60%
Technicals
Annualised · 30 sessions RSI 14
54.9
MA 50
150.25 ▲
MA 200
130.68 ▲
30-Session Vol
38.6%
Analyst ratings & fundamentals for Aspen Pharmacare Hldgs Ltd aren't available yet.
Why It Matters
Combined view Fundamentals vs Price Action
The latest SENS reads positive and the trend is up on both timeframes. Disclosure and chart agree — any move has more evidence behind it than a low-volume bounce.
Trend Structure
Price sits above both the 50- and 200-day moving averages. That is the cleanest technical configuration — pullbacks tend to be bought in this regime.
About Aspen Pharmacare Holdings Limited
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and markets specialty and branded pharmaceutical products in Africa, the Middle East, the Americas, Europe CIS, Australasia, and Asia. It operates through Commercial Pharmaceuticals and Manufacturing segments. The company offers injectables for therapeutic areas, such as anaesthetics, anticoagulants, antithrombotic agents, analgesics, and hormone replacement medicines under the Arixtra, Diprivan, Fraxiparine, Marcaine, Sustanon, and Xylocaine brands; over-the-counter medicines under the Emla, Maltofer, Ovestin, Solpadeine, and Xylocaine brands; and prescription products for anti-inflammatories, immunosuppressants, hypothyroidism, anti-gout, analgesics, and corticosteroids under the Eltroxin, Imuran, Lipitor, Lyrica, and Zyloric brands. It also manufactures active pharmaceutical ingredients, finished dose forms, and heparins, as well as steriles, oral solid doses, liquids, semi-solids, and biologicals. The company exports its products. Aspen Pharmacare Holdings Limited was founded in 1850 and is headquartered in Durban, South Africa.
- Exchange
- Johannesburg
- Currency
- ZAc
- Employees
- 9,128
- Country
- South Africa
- Website
- https://www.aspenpharma.com
Related
Build your JSE watchlist.
Save tickers, follow new SENS announcements, and get personalised daily analysis.
→ Create Free Account